CRSP:NSD-Crispr Therapeutics AG (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 42.12

Change

0.00 (0.00)%

Market Cap

USD 4.33B

Volume

1.43M

Analyst Target

USD 95.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 76.39B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 18.65B
SMMT Summit Therapeutics PLC

N/A

USD 17.01B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B

ETFs Containing CRSP

XDNA 15.28 % 0.00 %

N/A

N/A
ARKG ARK Genomic Revolution ET.. 8.30 % 0.75 %

N/A

USD 1.06B
ARCG:LSE ARK Genomic Revolution UC.. 7.74 % 0.00 %

N/A

USD 9.51M
ARKG:LSE ARK Genomic Revolution UC.. 6.32 % 0.00 %

N/A

USD 9.33M
ARKK ARK Innovation ETF 5.70 % 0.75 %

N/A

USD 5.23B
ARCK:LSE ARK Innovation UCITS ETF .. 4.97 % 0.00 %

N/A

USD 0.04B
GNOG:LSE Global X Genomics & Biote.. 4.53 % 0.00 %

N/A

USD 9.42M
GNOM Global X Genomics & Biote.. 4.46 % 0.00 %

N/A

USD 0.06B
NXTE Investment Managers Serie.. 4.01 % 0.00 %

N/A

N/A
ARKK:LSE ARK Innovation UCITS ETF .. 3.97 % 0.00 %

N/A

USD 0.04B
LS:CA 3.11 % 2.21 %

N/A

N/A
AIIQ 0.00 % 0.79 %

N/A

N/A
ERSX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.01% 78% C+ 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.01% 78% C+ 82% B
Trailing 12 Months  
Capital Gain -42.26% 50% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.26% 50% F 24% F
Trailing 5 Years  
Capital Gain 12.59% 72% C 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.59% 72% C 38% F
Average Annual (5 Year Horizon)  
Capital Gain -2.51% 48% F 32% F
Dividend Return -2.51% 48% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 53.05% 62% D 37% F
Risk Adjusted Return -4.73% 45% F 31% F
Market Capitalization 4.33B 94% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector